medigraphic.com
ISSN 0210-5187 (Electronic)

2017, Number 3

Next >>

Med Cutan Iber Lat Am 2017; 45 (3)

Cutaneous Melanoma

Stengel FM

Language: Spanish
References: 33
Page: 173-177
PDF size: 265.23 Kb.


Text Extraction

No abstract.


REFERENCES

  1. En: http://globocan.iarc.fr

  2. Whiteman DC, Green AC, Olsen CM. The growing burden of invasive melanoma: projections of incidence rates and numbers of new cases in six susceptible populations through 2031. J Invest Dermatol. 2016; 136 (6): 1161-1171.

  3. Bastian BC. The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia. Annu Rev Pathol. 2014; 9: 239-271.

  4. Ascierto PA, Agarwala SS, Ciliberto G, Demaria S, Dummer R, Duong CPM et al. Future perspectives in melanoma research “melanoma Bridge”, Napoli, November 30th-3rd December 2016. J Transl Med. 2017; 15 (1): 236.

  5. Luke JJ, Flaherty KT, Ribas A, Long GV. Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin Oncol. 2017; 14 (8): 463-482.

  6. Garbutcheon-Singh KB, Dixit S, Lee A, Brown P, Smith SD. Assessment of attitudes towards sun-protective behaviour in Australians: A cross-sectional study. Australas J Dermatol. 2016; 57 (2): 102-107.

  7. Diffey B, Cadars B. An appraisal of the need for infrared radiation protection in sunscreens. Photochem Photobiol Sci. 2016; 15 (3): 361-364.

  8. Tyagi N, Srivastava SK, Arora S, Omar Y, Ijaz ZM, Al-Ghadhban A et al. Comparative analysis of the relative potential of silver, Zinc-oxide and titanium-dioxide nanoparticles against UVB-induced DNA damage for the prevention of skin carcinogenesis. Cancer Lett. 2016; 383 (1): 53-61.

  9. Reddy BY, Miller DM, Tsao H. Somatic driver mutations in melanoma. Cancer. 2017; 123 (S11): 2104-2117.

  10. Mar VJ, Chamberlain AJ, Kelly JW, Murray WK, Thompson JF. Clinical practice guidelines for the diagnosis and management of melanoma: melanomas that lack classical clinical features. Med J Aust. 2017; 207 (8): 348-350.

  11. Esteva A, Kuprel B, Novoa RA, Ko J, Swetter SM, Blau HM et al. Dermatologist-level classification of skin cancer with deep neural networks. Nature. 2017; 542 (7639): 115-118.

  12. Ferris LK, Jansen B, Ho J, Busam KJ, Gross K, Hansen DD et al. Utility of a noninvasive 2-gene molecular assay for cutaneous melanoma and effect on the decision to biopsy. JAMA Dermatol. 2017; 153 (7): 675-680.

  13. Loeb S, Ventimiglia E, Salonia A, Folkvaljon Y, Stattin P. Meta-analysis of the association between phosphodiesterase inhibitors (PDE5Is) and risk of melanoma. J Natl Cancer Inst. 2017; 109 (8). doi: 10.1093/jnci/djx086.

  14. Stigall LE, Brodland DG, Zitelli JA. The use of Mohs micrographic surgery (MMS) for melanoma in situ (MIS) of the trunk and proximal extremities. J Am Acad Dermatol. 2016; 75 (5): 1015-1021.

  15. Gaudy-Marqueste C, Perchenet AS, Taséi AM, Madjlessi N, Magalon G, Richard MA et al. The “spaghetti technique”: an alternative to Mohs surgery or staged surgery for problematic lentiginous melanoma (lentigo maligna and acral lentiginous melanoma). J Am Acad Dermatol. 2011; 64 (1): 113-118.

  16. Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017; 547 (7662): 217-221.

  17. Olmeda D, Cerezo-Wallis D, Riveiro-Falkenbach E, Pennacchi PC, Contreras-Alcalde M, Ibarz N et al. Whole-body imaging of lymphovascular niches identifies pre-metastatic roles of midkine. Nature. 2017; 546 (7660): 676-680.

  18. Hamid O, Gajewski TF, Frankel AE, Bauer TM, Olszanski AJ, Luke JJ et al. Epacadostat plus pembrolizumab in patients with advanced melanoma: Phase 1 and 2 efficacy and safety results from ECHO-202/KEYNOTE-037. Ann Oncol. 2017; 28 Suppl 5: v428-v448.

  19. Orloff M. Spotlight on talimogene laherparepvec for the treatment of melanoma lesions in the skin and lymph nodes. Oncolytic Virother. 2016; 5: 91-98.

  20. Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med. 2010; 207 (10): 2187-2194.

  21. G. Long. Abstracts. Final Conference. World Congress Of Melanoma. Brisbane, Australia, October 2017

  22. Faries MB, Thompson JF, Cochran AJ, Andtbacka RH, Mozzillo N, Zager JS et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med. 2017; 376 (23): 2211-2222.

  23. Leiter U, Stadler R, Mauch C, Hohenberger W, Brockmeyer N, Berking C et al. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2016; 17 (6): 757-767.

  24. Moreno-Ramírez D, Vidal-Sicart S, Puig S, Malvehy J. ¿Debe abandonarse la disección ganglionar inmediata en el paciente con metástasis de melanoma en el ganglio centinela? Med Clin (Barc). 2017 [En prensa]. doi: org/10.1016/j.medcli.2017.08.013.

  25. Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017; 67 (6): 472-492.

  26. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S et al. Mutations of the BRAF gene in human cancer. Nature. 2002; 417 (6892): 949-954.

  27. Luke JJ, Flaherty KT, Ribas A, Long GV. Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin Oncol. 2017; 14 (8): 463-482.

  28. Brochez L, Chevolet I, Kruse V. The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy. Eur J Cancer. 2017; 76: 167-182.

  29. Long GV, Hauschild A, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med. 2017; 377 (19): 1813-1823.

  30. Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017; 377 (19): 1824-1835.

  31. Long GV, Atkinson V, Menzies AM, Guminski AD, Kaur SS, Brown MP et al. A randomized phase II study of nivolumab or nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases (mets): The Anti-PD1 Brain Collaboration (ABC). J Clin Oncol. 2017; 35 (15 suppl): 9508.

  32. Abdul-Hassan TH, Forsyth PA, Algazi AP, Hamid O, Hodi FS, Moschos SJ et al. Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: Results of the phase II study CheckMate 204. J Clin Oncol. 2017; 35 (15 suppl): 9507.

  33. Busser B, Lupo J, Sancey L, Mouret S, Faure P, Plumas J et al. Plasma circulating tumor DNA levels for the monitoring of melanoma patients: landscape of available technologies and clinical applications. Biomed Res Int. 2017; 2017: 5986129.




2020     |     www.medigraphic.com